Publication: Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations
Issued Date
2012-01-01
Resource Type
ISSN
13993046
13973142
13973142
Other identifier(s)
2-s2.0-85028096661
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Transplantation. Vol.16, No.8 (2012)
Suggested Citation
Kanchana Tangnararatchakit, Wiwat Tirapanich, Usanarat Anurathapan, Wiwat Tapaneya-Olarn, Samart Pakakasama, Saengsuree Jootar, Shimon Slavin, Suradej Hongeng Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations. Pediatric Transplantation. Vol.16, No.8 (2012). doi:10.1111/j.1399-3046.2012.01701.x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/15089
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations
Other Contributor(s)
Abstract
The present case report represents a successful attempt to induce transplantation tolerance to organ allograft by combined administration of donor hematopoietic cells and kidney based on in vivo deletion of alloreactive host-vs-graft and graft-vs-host alloreactive T cells following non-myeloablative conditioning. We were able to induce mixed and eventually full donor chimerism and tolerance of kidney allograft in a 15-yr-old male with ESRD after cisplatin treatment and autologous HSCT for mediastinal germ cell tumor. Our approach to induce tolerance was based on preferential depletion of alloreactive T cells induced by exposure to donor's alloantigens and administration of cyclophosphamide at day 2 and day 3 after stem cell infusion. Additional non-specific immunosuppression as part of the conditioning included exposure to two fractions of TLI, treatment with alemtuzumab (monoclonal anti-CD52) and short-term conventional IS treatment to avoid early graft loss, because of request of IRB. Using this approach, with rapid tapering of all conventional IS treatment, the patient maintains good renal functions without evidence of both acute and chronic rejection for 32 months off all medications. © 2012 John Wiley & Sons A/S.